soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π Oral Semaglutide and Cardiovascular Outcomes
Description
Clinical efficacy depends on the semaglutide molecule itself, not the brand name
Thats another reason theyre not going to see the long-term effects. Diede agreed that, at current prices, the economics are difficult to justify purely on cost savings
[DOI] [PubMed] [Google Scholar] 80.Parkman HP, Harris AD, Miller MA, et al
Safety Considerations and Side Effects GLP-1 agonists are generally well-tolerated, with common side effects including nausea, vomiting, and diarrhea, especially during the initial stages of treatment
